Top Markets
Coin of the day
Actuate Therapeutics Inc Actuate Therapeutics Inc

Actuate Therapeutics Inc

ACTU
Rank in Stocks #28698
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the... Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Share Price
$1.05
Market Cap
$25.12M
Change (1 day)
0.00%
Change (1 year)
-86.83%
Country
US
Trade Actuate Therapeutics Inc (ACTU)

Category

P/S ratio for Actuate Therapeutics Inc (ACTU)
P/S ratio as of 2026 TTM: 0
According to Actuate Therapeutics Inc latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Actuate Therapeutics Inc from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
11.28 -
US
10.13 -
NL
2.95 -
AU
- -
CH